AngioDynamics (ANGO)
(Delayed Data from NSDQ)
$7.42 USD
-0.13 (-1.72%)
Updated Aug 27, 2024 03:59 PM ET
After-Market: $7.40 -0.02 (-0.27%) 5:36 PM ET
1-Strong Buy of 5 1
B Value B Growth F Momentum B VGM
Income Statements
Fiscal Year end for AngioDynamics, Inc falls in the month of May .
All items in Millions except EPS data.
5/31/24 | 5/31/23 | 5/31/22 | 5/31/21 | 5/31/20 | |
---|---|---|---|---|---|
Sales | 304 | 339 | 316 | 291 | 264 |
Cost Of Goods | 149 | 165 | 150 | 134 | 114 |
Gross Profit | 155 | 174 | 166 | 157 | 150 |
Selling & Adminstrative & Depr. & Amort Expenses | 347 | 225 | 194 | 192 | 317 |
Income After Depreciation & Amortization | -192 | -51 | -28 | -35 | -167 |
Non-Operating Income | -1 | -1 | -1 | 0 | 0 |
Interest Expense | -2 | 3 | 1 | 1 | 1 |
Pretax Income | -192 | -54 | -30 | -36 | -168 |
Income Taxes | -7 | -2 | -3 | -5 | -1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -184 | -52 | -27 | -32 | -167 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -184 | -52 | -27 | -32 | -167 |
Depreciation Footnote | 5/31/24 | 5/31/23 | 5/31/22 | 5/31/21 | 5/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -5 | -6 | 1 | -9 | -143 |
Depreciation & Amortization (Cash Flow) | 187 | 45 | 29 | 26 | 24 |
Income After Depreciation & Amortization | -192 | -51 | -28 | -35 | -167 |
Earnings Per Share Data | 5/31/24 | 5/31/23 | 5/31/22 | 5/31/21 | 5/31/20 |
---|---|---|---|---|---|
Average Shares | 40.18 | 39.48 | 39.01 | 38.34 | 37.96 |
Diluted EPS Before Non-Recurring Items | -0.38 | -0.06 | 0.00 | 0.05 | 0.09 |
Diluted Net EPS (GAAP) | -4.59 | -1.33 | -0.68 | -0.82 | -4.39 |
Fiscal Year end for AngioDynamics, Inc falls in the month of May .
All items in Millions except EPS data.
5/31/24 | 2/29/24 | 11/30/23 | 8/31/23 | 5/31/23 | |
---|---|---|---|---|---|
Sales | 70.98 | 75.18 | 79.07 | 78.68 | 91.07 |
Cost Of Goods | 32.47 | 39.32 | 38.81 | 38.62 | 44.71 |
Gross Profit | 38.52 | 35.86 | 40.26 | 40.06 | 46.36 |
SG&A, R&D, and Dept/Amort Expenses | 52.96 | 235.76 | 53.38 | 5.03 | 67.20 |
Income After SG&A, R&D, and Dept/Amort Expenses | -14.44 | -199.90 | -13.12 | 35.03 | -20.84 |
Non-Operating Income | -0.26 | 0.16 | 0.50 | -0.17 | -0.13 |
Interest Expense | -1.61 | 0.00 | 0.00 | 0.00 | 0.90 |
Pretax Income | -14.14 | -199.74 | -12.62 | 34.86 | -21.87 |
Income Taxes | -0.69 | -12.00 | 16.43 | -11.02 | -0.40 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -13.45 | -187.74 | -29.05 | 45.88 | -21.47 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -13.45 | -187.74 | -29.05 | 45.88 | -21.47 |
Earnings Per Share Data | 5/31/24 | 2/29/24 | 11/30/23 | 8/31/23 | 5/31/23 |
---|---|---|---|---|---|
Average Shares | 40.43 | 40.23 | 40.22 | 39.97 | 39.61 |
Diluted EPS Before Non-Recurring Items | -0.06 | -0.16 | -0.05 | -0.12 | 0.02 |
Diluted Net EPS (GAAP) | -0.35 | -4.67 | -0.72 | 1.15 | -0.55 |